

Registered number: 09559128

AIMMUNE THERAPEUTICS UK LIMITED

ABBREVIATED ACCOUNTS

FOR THE PERIOD ENDED 31 DECEMBER 2015

SATURDAY



A5FP3IE1

A20

17/09/2016

#372

COMPANIES HOUSE

AIMMUNE THERAPEUTICS UK LIMITED

**INDEPENDENT AUDITORS' REPORT TO AIMMUNE THERAPEUTICS UK LIMITED
UNDER SECTION 449 OF THE COMPANIES ACT 2006**

We have examined the abbreviated accounts set out on pages 2 to 5, together with the financial statements of AIMMUNE THERAPEUTICS UK LIMITED for the period ended 31 December 2015 prepared under section 396 of the Companies Act 2006.

This report is made solely to the company in accordance with section 449 of the Companies Act 2006. Our work has been undertaken so that we might state to the company those matters we are required to state to it in a special Auditors' report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the company, for our work, for this report, or for the opinions we have formed.


RESPECTIVE RESPONSIBILITIES OF DIRECTORS AND AUDITORS

The directors are responsible for preparing the abbreviated accounts in accordance with section 444 of the Companies Act 2006. It is our responsibility to form an independent opinion as to whether the company is entitled to deliver abbreviated accounts to the Registrar of Companies and whether the abbreviated accounts have been properly prepared in accordance with the regulations made under that section and to report our opinion to you.

We conducted our work in accordance with Bulletin 2008/4 issued by the Auditing Practices Board. In accordance with that Bulletin we have carried out the procedures we consider necessary to confirm, by reference to the financial statements, that the company is entitled to deliver abbreviated accounts and that the abbreviated accounts are properly prepared.

OPINION ON FINANCIAL STATEMENTS

In our opinion the company is entitled to deliver abbreviated accounts prepared in accordance with section 444(3) of the Companies Act 2006, and the abbreviated accounts on pages 2 to 5 have been properly prepared in accordance with the regulations made under that section.



Russel Byrd ACA FCCA (Senior statutory auditor)

for and on behalf of
Randall & Payne LLP

Chargrove House
Shurdington Road
Shurdington
Cheltenham
Gloucestershire
GL51 4GA

Date:

15th September 2016

AIMMUNE THERAPEUTICS UK LIMITED
REGISTERED NUMBER: 09559128

ABBREVIATED BALANCE SHEET
AS AT 31 DECEMBER 2015

	Note	£	2015 £
FIXED ASSETS			
Tangible assets	3		7,624
CURRENT ASSETS			
Debtors		68,901	
Cash at bank		54,238	
		<u>123,139</u>	
CREDITORS: amounts falling due within one year		<u>(124,356)</u>	
NET CURRENT LIABILITIES			<u>(1,217)</u>
TOTAL ASSETS LESS CURRENT LIABILITIES			<u>6,407</u>
CAPITAL AND RESERVES			
Called up share capital	4		1,000
Profit and loss account			<u>5,407</u>
SHAREHOLDERS' FUNDS			<u>6,407</u>

The abbreviated accounts, which have been prepared in accordance with the special provisions relating to companies subject to the small companies regime within Part 15 of the Companies Act 2006, were approved and authorised for issue by the board and were signed on its behalf on *SEPTEMBER 8, 2016*


W DeSouza
Director

The notes on pages 3 to 5 form part of these financial statements.

AIMMUNE THERAPEUTICS UK LIMITED

NOTES TO THE ABBREVIATED ACCOUNTS
FOR THE PERIOD ENDED 31 DECEMBER 2015

1. ACCOUNTING POLICIES

1.1 Basis of preparation of financial statements

The full financial statements, from which these abbreviated accounts have been extracted, have been prepared under the historical cost convention and in accordance with the Financial Reporting Standard for Smaller Entities (effective January 2015).

1.2 Going concern

The directors have prepared the financial statements on a going concern basis, which assumes that the company will achieve sufficient financial resources, in order to meet its short and medium term liabilities. The company relies on the support of its parent company, Aimune Therapeutics Inc, formerly Allergen Research Corporation which has confirmed that it will continue to provide this for the foreseeable future.

1.3 Cash flow

The financial statements do not include a Cash flow statement because the company, as a small reporting entity, is exempt from the requirement to prepare such a statement under the Financial Reporting Standard for Smaller Entities (effective January 2015).

1.4 Turnover

Turnover comprises revenue recognised by the company in respect of goods and services supplied during the period, exclusive of Value Added Tax and trade discounts.

The company is contracted by its parent company, Aimune Therapeutics Inc, formerly Allergen Research Corporation, to provide marketing and sales services within specified contracted regions. The company is remunerated by its parent company for these services.

1.5 Tangible fixed assets and depreciation

Tangible fixed assets are stated at cost less depreciation. Depreciation is provided at rates calculated to write off the cost of fixed assets, less their estimated residual value, over their expected useful lives on the following bases:

Office equipment	Straight line over 3 years
------------------	----------------------------

1.6 Operating leases

Rentals under operating leases are charged to the Profit and Loss account on a straight line basis over the lease term.

Benefits received and receivable as an incentive to sign an operating lease are recognised on a straight line basis over the period until the date the rent is expected to be adjusted to the prevailing market rate.

AIMMUNE THERAPEUTICS UK LIMITED

**NOTES TO THE ABBREVIATED ACCOUNTS
FOR THE PERIOD ENDED 31 DECEMBER 2015**

1. ACCOUNTING POLICIES (continued)

1.7 Foreign currencies

Monetary assets and liabilities denominated in foreign currencies are translated into sterling at rates of exchange ruling at the balance sheet date.

Transactions in foreign currencies are translated into sterling at the rate ruling on the date of the transaction.

Exchange gains and losses are recognised in the Profit and loss account.

1.8 Share options

The parent company, Aimmune Therapeutics Inc has granted options over its shares to employees of Aimmune Therapeutics UK Limited. Further details are provided in Note 3.

2. SHARE BASED PAYMENTS

	Number of share	Number of employees	Market value \$
Granted 13 May 2015	263,400	1	3.02
Granted 9 July 2015	34,900	1	6.29
Granted 28 October 2015	7,231	1	15.54
Carried forward at 31 December 2015	<u>305,531</u>	<u>3</u>	

3. TANGIBLE FIXED ASSETS

	£
Cost	
At 24 April 2015	-
Additions	9,445
At 31 December 2015	<u>9,445</u>
Depreciation	
At 24 April 2015	-
Charge for the period	1,821
At 31 December 2015	<u>1,821</u>
Net book value	
At 31 December 2015	<u>7,624</u>

AIMMUNE THERAPEUTICS UK LIMITED

NOTES TO THE ABBREVIATED ACCOUNTS
FOR THE PERIOD ENDED 31 DECEMBER 2015

4. SHARE CAPITAL

	2015 £
Allotted, called up and fully paid	
1,000 Ordinary shares of £1 each	1,000

5. ULTIMATE PARENT UNDERTAKING AND CONTROLLING PARTY

The company is a wholly owned subsidiary undertaking of Aimmune Therapeutics Inc, formerly Allergen Research Corporation, a company incorporated in the United States of America.

The largest and smallest group in which the results of the company are consolidated is that headed by Aimmune Therapeutics Inc. The consolidated financial statements of the company may be obtained from Aimmune Therapeutics Inc. 8000 Marina Boulevard, Suite 300, Brisbane, CA 94005, United States of America). No other group financial statements include the results of the company.